{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:20:53Z","timestamp":1769833253271,"version":"3.49.0"},"reference-count":51,"publisher":"Japan Atherosclerosis Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.5551\/jat.45799","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T22:33:14Z","timestamp":1545431594000},"page":"659-669","source":"Crossref","is-referenced-by-count":19,"title":["Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus"],"prefix":"10.5551","volume":"26","author":[{"given":"Takashi","family":"Yamaguchi","sequence":"first","affiliation":[{"name":"Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohji","family":"Shirai","sequence":"additional","affiliation":[{"name":"Mihama Katori Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiji","family":"Nagayama","sequence":"additional","affiliation":[{"name":"Nagayama Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rena","family":"Oka","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Imamura","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Sato","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Kawana","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ohira","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhito","family":"Saiki","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Tatsuno","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362: 801-809","DOI":"10.1038\/362801a0"},{"key":"2","unstructured":"2) Singh RB, Mengi SA, Xu YJ, Ameja AS, Dhalla NS. Pathogenesis of atherosclerosis: A multifactorial process. Exp. Clin. Cardiol. 2002; 7: 40-53"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Miyata M. Noninvasive Assessment of Arterial Stiffness Using Oscillometric Methods: baPWV, CAVI, API, and AVI. J Atheroscler Thromb 2018; 25: 790-791","DOI":"10.5551\/jat.ED098"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb 2006; 13: 101-107","DOI":"10.5551\/jat.13.101"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Sato Y, Nagayama D, Saiki A, Watanabe R, Watanabe Y, Imamura H, Yamaguchi T, Ban N, Kawana H, Nagumo A, Ohira M, Endo K, Kurosu T, Tomaru T, Shirai K, Tatsuno I. Cardio-Ankle Vascular Index is Independently Associated with Future Cardiovascular Events in Outpatients with Metabolic Disorders. J Atheroscler Thromb 2016; 23: 596-605","DOI":"10.5551\/jat.31385"},{"key":"6","unstructured":"6) Nagayama D, Saiki A, Endo K, Yamaguchi T, Ban N, Kawana H, Ohira M, Oyama T, Miyashita Y, Shirai K. Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients. Int. J. Clin. Pract. 2010; 64: 1796-1801"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Miyashita Y, Saiki A, Endo K, Ban N, Yamaguchi T, Kawana H, Nagayama D, Ohira M, Oyama T, Shirai K. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. J Atheroscler Thromb 2009; 16: 621-626","DOI":"10.5551\/jat.497"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Yamanaka M, Sakuma M, Matsushita A, Tanaka S, Yamamoto Y, Asai T, Arai H. The Effects of Long-Term Dietary Therapy on Patients with Hypertriglyceridemia. J Atherscler Thromb 2019; 26: 39-49","DOI":"10.5551\/jat.42440"},{"key":"9","unstructured":"9) Endo K, Saiki A, Ohira M, Miyashita Y, Shirai K. Cardio-ankle vascular index may reflect endothelial function in type 2 diabetes. Int. J. Clin. Pract. 2011; 65: 1200-1201"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Nagayama D, Endo K, Ohira M, Yamaguchi T, Ban N, Kawana H, Nagumo A, Saiki A, Oyama T, Miyashita Y, Shirai K. Effects of body weight reduction on cardio-ankle vascular index (CAVI). Obes. Res. Clin. Pract. 2013; 7: e139-e145","DOI":"10.1016\/j.orcp.2011.08.154"},{"key":"11","unstructured":"11) Nagayama D, Watanabe Y, Saiki A, Shirai K, Tatsuno I. Lipid Parameters are Independently Associated with Cardio-Ankle Vascular Index (CAVI) in Healthy Japanese Subjects. J. Atherscler. Thromb. 2018; 25: 621-623"},{"key":"12","unstructured":"12) Haffner SM, Lehto S, R\u00f6nnemaa T, Py\u00f6r\u00e4l\u00e4 K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998; 339: 229-234"},{"key":"13","unstructured":"13) Juutilainen A, Lehto S, R\u00f6nnemaa T, Py\u00f6r\u00e4l\u00e4 K , Laakso M. Type 2 diabetes as a \u201ccoronary heart disease equivalent\u201d: an 18-year prospective population-based study in Finnish subjects. Diabetes. Care. 2005; 28: 2901-2907"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kameda K, Matsuzawa Y, Kubo M, Ishikawa K, Maejima I, Yamamura T, Yamamoto A, Tarui S. Increased frequency of lipoprotein disorders similar to type III hyperlipoproteinemia in survivors of myocardial infarction in Japan. Atherosclerosis. 1984; 51: 241-249","DOI":"10.1016\/0021-9150(84)90171-0"},{"key":"15","unstructured":"15) Hitsumoto T, Iizuka T, Takahashi M, Yoshinaga K, Matsumoto J, Shimizu K, Kaku M, Sugiyama Y, Sakurai T, Aoyagi K, Kanai M, Noike H, Ohsawa H, Watanabe H, Shirai K. Relationship between insulin resistance and oxidative stress in vivo. J. Cardiol. 2003; 42: 119-127"},{"key":"16","unstructured":"16) Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur. Heart. J. 1998; 19 Suppl: M8-14"},{"key":"17","unstructured":"17) Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Ohashi Y, Akanuma Y, Yamada N.; Japan Diabetes Complications Study Group. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J. Clin. Endocrinol. Metab. 2011; 96: 3448-3456"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidemia and future perspectives. Atherosclerosis. 2003; 171: 1-13","DOI":"10.1016\/S0021-9150(03)00156-4"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000; 405: 421-424","DOI":"10.1038\/35013000"},{"key":"20","unstructured":"20) Guerre-Millo M, Gervois P, Rasp\u00e9 E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B. Peroxisome proliferatoractivated receptor alpha activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 2000; 275: 16638-16642"},{"key":"21","unstructured":"21) Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc. Diabetol. 2012; 11: 125"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Tenenbaum A, Fisman EZ. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc. Diabetol. 2012; 11: 140","DOI":"10.1186\/1475-2840-11-140"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Totsuka M, Miyashita Y, Ito Y, Watanabe H, Murano T, Shirai K. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration. Atherosclerosis. 2000; 153: 175-179","DOI":"10.1016\/S0021-9150(00)00394-4"},{"key":"24","unstructured":"24) Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary\u2019s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes. Care. 1998; 21: 641-648"},{"key":"25","unstructured":"25) Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch. Intern. Med. 2005; 165: 1154-1160"},{"key":"26","unstructured":"26) Zhu S, Su G, Meng QH. Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clin. Chem. 2006; 52: 2036-2042"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Ueno Y, Tanaka R, Yamashiro K, Miyamoto N, Hira K, Kurita N, Sakurai M, Urabe T, Shimada K, Miyazaki T, Daida H, Hattori N. Age Stratification and Impact of Eicosapentaenoic Acid and Docosahexaenoic Acid to Arachidonic Acid Ratios in Ischemic Stroke Patients. J Atheroscler Thromb. 2018; 25: 593-605","DOI":"10.5551\/jat.40691"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008; 197: 12-24","DOI":"10.1016\/j.atherosclerosis.2007.11.008"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007; 369: 1090-1098","DOI":"10.1016\/S0140-6736(07)60527-3"},{"key":"30","unstructured":"30) Satoh N, Shimatsu A, Kotani K, Himeno A, Majima T, Yamada K, Suganami T, Ogawa Y. Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens. Res. 2009; 32: 1004-1008"},{"key":"31","unstructured":"31) Kobayashi J, Hashimoto H, Fukamachi I, Tashiro J, Shirai K, Saito Y, Yoshida S. Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin. Chem. Acta. 1993; 216: 113-123"},{"key":"32","unstructured":"32) Hasegawa M. Fundamental research on human aortic pulse wave velocity. Jikei Medical Journal 1970; 85: 742-760"},{"key":"33","unstructured":"33) Migdalis IN, Gerolimou B, Kozanidou, G, Voudouris G, Hatzigakis SM, Petropoulos A. Effect of gemfibrozil on early carotid atherosclerosis in diabetic patients with hyperlipidaemia. Int. Angiol. 1997; 16: 258-261"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, Target R, Levy BI. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension. 1995; 26: 485-490","DOI":"10.1161\/01.HYP.26.3.485"},{"key":"35","unstructured":"35) Yamashina A, Tomiyama H, Arai T, Koji Y, Yambe M, Motobe H, Glunizia Z, Yamamoto Y, Hori S. Nomogram of the relation of brachial-ankle pulse wave velocity with blood pressure. Hypertens. Res. 2003; 26: 801-806"},{"key":"36","unstructured":"36) Wilkinson IB, Cockcroft JR, Webb DJ. Pulse wave analysis and arterial stiffness. J. Cardiovasc. Phamacol. 1998; 32 Suppl 3: S33-37"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Miyashita Y, Endo K, Saiki A, Ban N, Yamaguchi T, Kawana H, Nagayama D, Ohira M, Oyama T, Shirai K. Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Athroscler Thromb 2009; 16: 539-545","DOI":"10.5551\/jat.281"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Von Schacky C. The role of omega-3 fatty acids in cardiovascular disease. Curr. Atheroscler. Rep. 2003; 5: 139-145","DOI":"10.1007\/s11883-003-0086-y"},{"key":"39","unstructured":"39) Ebisawa S, Kashima Y, Miyashita Y, Yamazaki S, Abe N, Saigusa T, Miura T, Motoki H, Izawa A, Ikeda U. Impact of endovascular therapy on oxidative stress in patients with peripheral artery disease. Circ. J. 2014; 78: 1445-1450"},{"key":"40","unstructured":"40) Nakajima A, Aoki Y, Shibata Y, Sonobe M, Terajima F, Takahashi H, Saito M, Taniguchi S, Yamada M, Nakagawa K. Identification of clinical parameters associated with serum oxidative stress in patients with rheumatoid arthritis. Mod. Rheumatol. 2014; 24: 926-930"},{"key":"41","unstructured":"41) Kato T, Umeda A, Miyagawa K, Takeda H, Adachi T, Toyoda S, Taguchi I, Inoue T, Node K. Varenicline-assisted smoking cessation decreases oxidative stress and restores endothelial function. Hypertens. Res. 2014; 37: 655-658"},{"key":"42","unstructured":"42) Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 45-51"},{"key":"43","unstructured":"43) Beltowski J, W\u00f3jcicka G, Mydlarczyk M, Jamorz A. The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma peroxidase 1 (PON1) activity. J. Physiol. Pharmacol. 2002; 53: 463-475"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Sheetz MJ, King GL. Molecular understanding of hyperglycemia\u2019s adverse effects for diabetic complications. JAMA. 2002; 288: 2579-2588","DOI":"10.1001\/jama.288.20.2579"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part 1: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003; 108: 1912-1916","DOI":"10.1161\/01.CIR.0000093660.86242.BB"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Schuster H, Fagerberg B, Edwards S, Halmos T, Lopatynski J, Stender S, Birketvedt GS, Tonstad S, Gause-Nilsson I, Halld\u00f3rsd\u00f3ttir S, Ohman KP.; SIR Investigators. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha\/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Atherosclerosis. 2008; 197: 355-362","DOI":"10.1016\/j.atherosclerosis.2007.05.029"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Goldenberg I, Benderly M, Sidi R, Boyko V, Tenenbaum A, Tanne D, Behar S. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Am. J. Cardiol. 2009; 103: 41-45","DOI":"10.1016\/j.amjcard.2008.08.033"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Kitajima K, Miura S, Matsuo Y, Uehara Y, Saku K. Newly developed PPAR-alpha agonist (R)-K-13675 inhibits the secretion of inflammatory markers without affecting cell proliferation or tube formation. Atherosclerosis. 2009; 203: 75-81","DOI":"10.1016\/j.atherosclerosis.2008.05.055"},{"key":"49","unstructured":"49) Zahradka P, Wright B, Fuerst M, Yurkova K, Molnar K, Taylor CG. Peroxisome proliferator-activated receptor alpha and gamma ligands differentially affect smooth muscle cell proliferation and migration. J. Pharmacol. Exp. Ther. 2006; 317: 651-659"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004; 109: 2097-2202","DOI":"10.1161\/01.CIR.0000126824.12785.B6"},{"key":"51","unstructured":"51) Teramoto T, Shirai K, Daida H, Yamada N. Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. Cardiovasc. Diabetol. 2012; 11: 29"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/26\/7\/26_45799\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T03:45:45Z","timestamp":1562384745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/26\/7\/26_45799\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.45799","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}